What is muscle-invasive bladder cancer?

It is a type of bladder cancer that invades the muscular wall of the bladder, requiring intensive treatment.

Is this the first approval of its kind?

Yes, this is the first approval for a PD-1 inhibitor plus antibody-drug conjugate regimen in muscle-invasive bladder cancer.

Padcev (enfortumab vedotin) is an antibody-drug conjugate that targets the Nectin-4 protein on cancer cells.

Merck (MRK) Wins FDA Nod for New Keytruda Bladder Cancer Use

Merck (NYSE:MRK) announced FDA approval for the expanded use of Keytruda and Keytruda QLEX in combination with Padcev for muscle-invasive bladder cancer. The decision is based on results from the pivotal Phase 3 KEYNOTE-B15 study.

July 15, 2026

2 min read

Source: Simply Wall St.

Merck (NYSE:MRK) has received U.S. FDA approval for the expanded use of Keytruda (pembrolizumab) and Keytruda QLEX in combination with Padcev (enfortumab vedotin) for patients with muscle-invasive bladder cancer (MIBC).

The Product

This is the first approval for a PD-1 inhibitor plus antibody-drug conjugate (ADC) regimen in this indication, regardless of cisplatin eligibility. The approval is based on the Phase 3 KEYNOTE-B15 trial, which demonstrated efficacy of the combination.

Pricing and Availability

Merck has not disclosed pricing details for the new indication, but the treatment is expected to be available immediately in the U.S.

Competition

Keytruda competes with other immunotherapies like Bristol Myers Squibb's Opdivo (nivolumab) and Roche's Tecentriq (atezolizumab). However, being the first PD-1/ADC combination in MIBC gives it a competitive edge.

Potential Impact on the Company

This approval strengthens Keytruda's position as a leading oncology drug and opens a new patient population. It is expected to contribute to Merck's oncology revenue growth.

Frequently Asked Questions

Keytruda (pembrolizumab) is a PD-1 inhibitor used to treat various cancers by boosting the immune system.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.